Q: I just sold a position in Regeneron, and I am looking to replace it with another name in the healthcare space. I already hold ISRG, but I am reticent to add to it while it seems to trade sideways. Lilly has performed well, but I am unsure if it is now fully valued.A recent interviewee on CNBC had mentioned Amgen and Gilead as names which could do well. Any suggestions for names to consider in the healthcare space? I’d be okay with both Canadian and US names. Thanks so much, and I look forward to your response.

Q: I have mostly income holdings with some large growth stocks (GOOG, META, AMGN, MSFT). Having sold UMAX now looking at HHIS or HDIV. HHIS seems to fit the bill of both growth and income. In a mostly value portfolio I would hold 1% or $16,000 of HHIS for income. Is this reasonable with some risk or is adding to HDIV a better choice? HHIS has a total value now of over 1B up from its initial few million. 80 year old income investor with a 5-10 year horizon.

Q: I am building a diversified portfolio of healthcare stocks. I own JNJ, AMGN, MDT, CVS and MRNA. These are 2.9%, 3.8%, 2.5%, 4% and 0.5% of my portfolio respectively. Is this a high quality portfolio? Would you recommend any changes?